CN115927608B - 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备 - Google Patents

用于预测胰腺癌发生风险的生物标志物、方法和诊断设备 Download PDF

Info

Publication number
CN115927608B
CN115927608B CN202210107161.5A CN202210107161A CN115927608B CN 115927608 B CN115927608 B CN 115927608B CN 202210107161 A CN202210107161 A CN 202210107161A CN 115927608 B CN115927608 B CN 115927608B
Authority
CN
China
Prior art keywords
pancreatic cancer
risk
marker
artificial sequence
cyyr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210107161.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115927608A (zh
Inventor
韩达
张朝
滕小艳
马倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhenzhida Biotechnology Shanghai Co ltd
Original Assignee
Zhenzhida Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhenzhida Biotechnology Shanghai Co ltd filed Critical Zhenzhida Biotechnology Shanghai Co ltd
Priority to CN202210107161.5A priority Critical patent/CN115927608B/zh
Priority to PCT/CN2023/072981 priority patent/WO2023143326A1/fr
Publication of CN115927608A publication Critical patent/CN115927608A/zh
Application granted granted Critical
Publication of CN115927608B publication Critical patent/CN115927608B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202210107161.5A 2022-01-28 2022-01-28 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备 Active CN115927608B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210107161.5A CN115927608B (zh) 2022-01-28 2022-01-28 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备
PCT/CN2023/072981 WO2023143326A1 (fr) 2022-01-28 2023-01-18 Biomarqueur pour prédire le risque de cancer du pancréas, procédé et dispositif de diagnostic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210107161.5A CN115927608B (zh) 2022-01-28 2022-01-28 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备

Publications (2)

Publication Number Publication Date
CN115927608A CN115927608A (zh) 2023-04-07
CN115927608B true CN115927608B (zh) 2023-10-10

Family

ID=86551103

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210107161.5A Active CN115927608B (zh) 2022-01-28 2022-01-28 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备

Country Status (2)

Country Link
CN (1) CN115927608B (fr)
WO (1) WO2023143326A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117604112B (zh) * 2024-01-23 2024-04-16 杭州华得森生物技术有限公司 用于胰腺癌诊断和预后判断的生物标志物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106844A2 (fr) * 2012-01-13 2013-07-18 Oncocyte Corporation Procédés et compositions pour le traitement et le diagnostic du cancer du pancréas
CN110499364A (zh) * 2019-07-30 2019-11-26 北京凯昂医学诊断技术有限公司 一种用于检测扩展型遗传病全外显子的探针组及其试剂盒和应用
CN110554189A (zh) * 2018-05-30 2019-12-10 中国科学院上海生命科学研究院 胰腺癌诊断标志物及其应用
CN113249479A (zh) * 2021-05-24 2021-08-13 大连医科大学附属第一医院 胰腺癌相关的lncRNA标志物、探针及检测试剂盒在胰腺癌诊断中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013134860A1 (fr) * 2012-03-16 2013-09-19 University Health Network Biomarqueurs du cancer et leurs procédés d'utilisation
JP6652916B2 (ja) * 2013-06-20 2020-02-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 膵臓がんを診断するための方法
US11795510B2 (en) * 2016-10-06 2023-10-24 The Johns Hopkins University Identification of epigenomic reprogramming in cancer and uses thereof
WO2020056162A1 (fr) * 2018-09-12 2020-03-19 Oregon Health & Science University Détection et/ou sous-typage de cellules hybrides circulantes qui sont en corrélation avec un stade et la survie
US20230183807A1 (en) * 2019-03-04 2023-06-15 Universitair Ziekenhuis Antwerpen Methylation status of gasdermin e gene as cancer biomarker
JP2021089221A (ja) * 2019-12-05 2021-06-10 国立大学法人北海道大学 前がん病変の検出方法及び前がん病変か否かの診断を補助する方法
CN112626218A (zh) * 2021-01-07 2021-04-09 浙江科技学院 一种用于预测胰腺癌转移风险的基因表达分类器、体外诊断试剂盒

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013106844A2 (fr) * 2012-01-13 2013-07-18 Oncocyte Corporation Procédés et compositions pour le traitement et le diagnostic du cancer du pancréas
CN110554189A (zh) * 2018-05-30 2019-12-10 中国科学院上海生命科学研究院 胰腺癌诊断标志物及其应用
CN110499364A (zh) * 2019-07-30 2019-11-26 北京凯昂医学诊断技术有限公司 一种用于检测扩展型遗传病全外显子的探针组及其试剂盒和应用
CN113249479A (zh) * 2021-05-24 2021-08-13 大连医科大学附属第一医院 胰腺癌相关的lncRNA标志物、探针及检测试剂盒在胰腺癌诊断中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COL10A1在胰腺癌中的表达和临床意义;陈况;中国优秀硕士学位论文全文数据库 医药卫生科技辑;摘要、第一部分 *
Evaluation of polymorphisms in microRNA-binding sites and pancreatic cancer risk in Chinese population;Ke J等;J Cell Mol Med;第24卷(第3期);摘要、第3.4节、第4节 *
Key genes associated with pancreatic cancer and their association with outcomes: A bioinformatics analysis;Wu J等;Mol Med Rep;第20卷(第2期);摘要、表I、表IV、第1346-1351页 *
利用生物信息学分析筛选胰腺癌发生的潜在基因及机制;杨明丽等;中国医科大学学报;第49卷(第02期);第134-138页 *

Also Published As

Publication number Publication date
CN115927608A (zh) 2023-04-07
WO2023143326A1 (fr) 2023-08-03

Similar Documents

Publication Publication Date Title
CN107326066B (zh) 用于膀胱癌检测的尿标记物
KR101857462B1 (ko) 췌장암 바이오마커 및 그것의 용도
JP5666136B2 (ja) 原発不明がんの原発巣を同定するための方法および材料
US7871774B2 (en) Markers for the diagnosis of lung cancer
US20170292956A1 (en) Markers for Detection of Gastric Cancer
KR101566368B1 (ko) 암 검출을 위한 소변 유전자 발현 비율
KR101317513B1 (ko) 대장암 또는 난소암 진단용 조성물, 진단키트 및 진단방법
JP2009509502A (ja) 原発不明がんの原発巣を同定するための方法および材料
JP2011525106A (ja) 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
KR101478826B1 (ko) 신규한 대장암 진단용 마커 및 이를 이용한 대장암 진단 키트
JP2007159491A (ja) 大腸がんの検査に使用する遺伝子セット
CN115927608B (zh) 用于预测胰腺癌发生风险的生物标志物、方法和诊断设备
CN113493829B (zh) 生物标志物在肺动脉高压诊疗中的应用
KR102156282B1 (ko) 뇌 종양의 예후 예측 방법
CN112626207B (zh) 一种用于区分非侵袭性和侵袭性无功能垂体腺瘤的基因组合
WO2011146937A1 (fr) Procédés et kits utiles dans le diagnostic du nsclc (cancer du poumon à grandes cellules)
CN110656169B (zh) 心房颤动的诊断标志物
CN114164273B (zh) 一种鳞癌的预后标志物、预后风险评估模型的建立方法及其应用
KR20190143417A (ko) 뇌 종양의 예후 예측 방법
CN110331207A (zh) 肺腺癌生物标志物及相关应用
CN113631723B (zh) 结核病标志物在结核病诊断和疗效评估中的应用
EP1682679B1 (fr) Marqueur moleculaire
KR102560020B1 (ko) 암의 진단용 조성물
CN113718032B (zh) 生物标志物在早期检测宫颈癌中的应用
CN116656811B (zh) 胰腺导管腺癌预后检测试剂盒及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant